• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
TLX 2.97% $15.24

TELIX PHARMACEUTICALS LIMITED - Corporate Spotlight

Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on... Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals and associated medical devices. The Company is developing a portfolio of clinical-stage products that focuses to address the unmet medical needs in oncology and rare diseases. Its core pipeline is focused on prostate cancer, renal cancer, brain cancer (glioma) and rare diseases (hematologic cancers and bone marrow conditioning). The Company’s lead programs include TLX591-CDx (Illuccix) / TLX591 for diagnosis and treatment of metastatic castrate-resistant prostate cancer, TLX250-CDx/TLX250 for diagnosis and treatment of renal (kidney) cancer, TLX101-CDx / TLX101 for diagnosis and treatment of glioblastoma (brain cancer), and TLX66-CDx (Scintimun) / TLX66 for the treatment of bone marrow conditioning and rare diseases. The Company also owns SENSEI radio-guided surgery business.More

No Corporate Spotlight currently available.

(20min delay)
Last
$15.24
Change
0.440(2.97%)
Mkt cap ! $5.036B
Open High Low Value Volume
$14.71 $15.24 $14.61 $17.69M 1.179M

Buyers (Bids)

No. Vol. Price($)
1 2333 $15.15
 

Sellers (Offers)

Price($) Vol. No.
$15.25 10000 2
View Market Depth
Last trade - 16.10pm 03/05/2024 (20 minute delay) ?
Last
$15.21
  Change
0.440 ( 2.60 %)
Open High Low Volume
$14.73 $15.24 $14.62 327752
Last updated 15.59pm 03/05/2024 ?
TLX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.